NO321569B1 - Anvendelse av IL-7 for behandling av en autoimmun sykdom samt fremgangsmate for fremstilling av et farmasoytisk preparat. - Google Patents
Anvendelse av IL-7 for behandling av en autoimmun sykdom samt fremgangsmate for fremstilling av et farmasoytisk preparat. Download PDFInfo
- Publication number
- NO321569B1 NO321569B1 NO19983917A NO983917A NO321569B1 NO 321569 B1 NO321569 B1 NO 321569B1 NO 19983917 A NO19983917 A NO 19983917A NO 983917 A NO983917 A NO 983917A NO 321569 B1 NO321569 B1 NO 321569B1
- Authority
- NO
- Norway
- Prior art keywords
- autoimmune
- cells
- production
- autoimmune disease
- treatment
- Prior art date
Links
- 108010002586 Interleukin-7 Proteins 0.000 title claims abstract description 63
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 37
- 238000011282 treatment Methods 0.000 title claims description 26
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000000704 Interleukin-7 Human genes 0.000 claims abstract description 62
- 229940100994 interleukin-7 Drugs 0.000 claims abstract description 57
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 34
- 108090000978 Interleukin-4 Proteins 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 18
- 102100032912 CD44 antigen Human genes 0.000 claims description 16
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 16
- 230000017307 interleukin-4 production Effects 0.000 claims description 14
- 230000001363 autoimmune Effects 0.000 claims description 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 13
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 11
- 210000004241 Th2 cell Anatomy 0.000 claims description 9
- 230000007812 deficiency Effects 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 206010062269 Adrenalitis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010036030 Polyarthritis Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 206010040628 Sialoadenitis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 208000005963 oophoritis Diseases 0.000 claims description 2
- 230000003950 pathogenic mechanism Effects 0.000 claims description 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000001050 sialadenitis Diseases 0.000 claims description 2
- 230000007547 defect Effects 0.000 abstract 1
- 230000007365 immunoregulation Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 26
- 102000004388 Interleukin-4 Human genes 0.000 description 25
- 206010012601 diabetes mellitus Diseases 0.000 description 25
- 229940028885 interleukin-4 Drugs 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000011740 C57BL/6 mouse Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010018473 Glycosuria Diseases 0.000 description 4
- 230000003832 immune regulation Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101000884281 Rattus norvegicus Signal transducer CD24 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 108010066312 streptavidin-tricolor Proteins 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9602501A FR2745185B1 (fr) | 1996-02-28 | 1996-02-28 | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
| PCT/FR1997/000343 WO1997031648A1 (fr) | 1996-02-28 | 1997-02-26 | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO983917D0 NO983917D0 (no) | 1998-08-26 |
| NO983917L NO983917L (no) | 1998-10-28 |
| NO321569B1 true NO321569B1 (no) | 2006-06-06 |
Family
ID=9489676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983917A NO321569B1 (no) | 1996-02-28 | 1998-08-26 | Anvendelse av IL-7 for behandling av en autoimmun sykdom samt fremgangsmate for fremstilling av et farmasoytisk preparat. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6713053B1 (es) |
| EP (1) | EP0883406B1 (es) |
| JP (1) | JP3138481B2 (es) |
| AT (1) | ATE264112T1 (es) |
| AU (1) | AU1929397A (es) |
| BR (1) | BR9707776A (es) |
| DE (1) | DE69728654T2 (es) |
| DK (1) | DK0883406T3 (es) |
| ES (1) | ES2217396T3 (es) |
| FR (1) | FR2745185B1 (es) |
| NO (1) | NO321569B1 (es) |
| PT (1) | PT883406E (es) |
| WO (1) | WO1997031648A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2745185B1 (fr) * | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
| US8298535B2 (en) | 2010-02-24 | 2012-10-30 | Rinat Neuroscience Corp. | Anti-IL-7 receptor antibodies |
| CN104769104A (zh) | 2011-12-12 | 2015-07-08 | 细胞药物有限公司 | 扩大t细胞的方法 |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| EP4089167A1 (en) | 2012-02-09 | 2022-11-16 | Baylor College of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| WO2015035063A2 (en) * | 2013-09-05 | 2015-03-12 | Sanford-Burnham Medical Research Institute | MODULATION OF γδT CELLS |
| WO2017049291A1 (en) | 2015-09-18 | 2017-03-23 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5032396A (en) * | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
| US5229115A (en) * | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
| US5474769A (en) * | 1991-03-08 | 1995-12-12 | Sterling Winthrop Inc. | Treatment of microbial infection by monocyte stimulation with interleukin-7 |
| US6576236B1 (en) * | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
| FR2745185B1 (fr) * | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
-
1996
- 1996-02-28 FR FR9602501A patent/FR2745185B1/fr not_active Expired - Lifetime
-
1997
- 1997-02-26 JP JP09530667A patent/JP3138481B2/ja not_active Expired - Lifetime
- 1997-02-26 ES ES97907134T patent/ES2217396T3/es not_active Expired - Lifetime
- 1997-02-26 DE DE69728654T patent/DE69728654T2/de not_active Expired - Lifetime
- 1997-02-26 AT AT97907134T patent/ATE264112T1/de active
- 1997-02-26 EP EP97907134A patent/EP0883406B1/fr not_active Expired - Lifetime
- 1997-02-26 US US09/125,168 patent/US6713053B1/en not_active Expired - Lifetime
- 1997-02-26 WO PCT/FR1997/000343 patent/WO1997031648A1/fr active IP Right Grant
- 1997-02-26 PT PT97907134T patent/PT883406E/pt unknown
- 1997-02-26 DK DK97907134T patent/DK0883406T3/da active
- 1997-02-26 AU AU19293/97A patent/AU1929397A/en not_active Abandoned
- 1997-02-26 BR BR9707776A patent/BR9707776A/pt not_active Application Discontinuation
-
1998
- 1998-08-26 NO NO19983917A patent/NO321569B1/no not_active IP Right Cessation
-
2004
- 2004-03-26 US US10/810,109 patent/US20040180037A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| FR2745185A1 (fr) | 1997-08-29 |
| JPH11508605A (ja) | 1999-07-27 |
| BR9707776A (pt) | 1999-07-27 |
| NO983917D0 (no) | 1998-08-26 |
| AU1929397A (en) | 1997-09-16 |
| FR2745185B1 (fr) | 1998-05-15 |
| EP0883406B1 (fr) | 2004-04-14 |
| NO983917L (no) | 1998-10-28 |
| WO1997031648A1 (fr) | 1997-09-04 |
| US6713053B1 (en) | 2004-03-30 |
| JP3138481B2 (ja) | 2001-02-26 |
| DE69728654T2 (de) | 2005-03-24 |
| EP0883406A1 (fr) | 1998-12-16 |
| PT883406E (pt) | 2004-08-31 |
| ATE264112T1 (de) | 2004-04-15 |
| DK0883406T3 (da) | 2004-08-02 |
| US20040180037A1 (en) | 2004-09-16 |
| DE69728654D1 (de) | 2004-05-19 |
| ES2217396T3 (es) | 2004-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kelley et al. | Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. | |
| Murphy et al. | New strategies for preventing graft-versus-host disease | |
| US7592007B2 (en) | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies | |
| JP2547162B2 (ja) | 哺乳動物における異系移植片拒否反応を抑制するための方法と組成物 | |
| JP2000509604A (ja) | サプレッサー細胞集団を生成するためのインターロイキン―１０の使用 | |
| US5624938A (en) | Use of chloroquine to treat multiple sclerosis | |
| EP0637249A1 (en) | Suppression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides | |
| Willenborg et al. | Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. | |
| Pankewycz et al. | A protective NOD islet‐infiltrating CD8+ T cell clone, IS 2.15, has in vitro immunosuppressive properties | |
| NO321569B1 (no) | Anvendelse av IL-7 for behandling av en autoimmun sykdom samt fremgangsmate for fremstilling av et farmasoytisk preparat. | |
| Fuss | Cytokine network in inflammatory bowel disease | |
| Hawley et al. | Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas | |
| Gorczynski et al. | A ROLE FOR PERSISTING ANTIGEN, ANTIGEN PRESENTATION, AND ICAM-1 IN INCREASED RENAL GRAFT SURVIVAL AFTER ORAL OR PORTAL VEIN DONOR-SPECIFIC IMMUNIZATION1 | |
| Streilein et al. | Effect of intraocular gamma-interferon on immunoregulatory properties of iris and ciliary body cells. | |
| Ito et al. | Regulation of autoimmune diabetes by interleukin 3-dependent bone marrow-derived cells in NOD mice | |
| JPH11510806A (ja) | 免疫抑制治療のためのインターロイキン１０およびシクロスポリンの併用 | |
| Terres et al. | The role of IL-4 and IL-10 cytokines in controlling an anti-tumor response in vivo. | |
| Ajitsu et al. | In vivo immunologic intervention in age-related T cell defects in murine gut-associated lymphoid tissues by IL2 | |
| Ten Berge et al. | A longitudinal study on the effects of azathioprine and high doses of prednisone on the immune system of kidney-transplant recipients | |
| Saoudi et al. | Prevention of experimental autoimmune uveoretinitis and experimental autoimmune pinealitis in (Lewis x Brown-Norway) F1 rats by HgCl2 injections. | |
| US20020048579A1 (en) | Ex vivo treatment of allogeneic and xenogeneic donor T-cells containing compositions (bone marrow) using gp39 antagonists and use thereof | |
| CA2247179C (fr) | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant | |
| Mirakian et al. | Inappropriate HLA molecule expression in epithelial cells: relevance for human autoimmunity | |
| KR20130110283A (ko) | 면역조절 ｔ 세포를 포함하는 자가면역 질환 세포치료제 | |
| Girvin | Regulation of T cell activation in experimental autoimmune encephalomyelitis: Significance of CD28-mediated costimulation and immune function of CNS-resident cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |